Infosys Technologies and Elan Pharmaceuticals (ELN) Apply Co-creation Model to Transform Discovery Research
2/2/2010 9:27:18 AM
London, UK – February 1, 2010: Infosys Technologies Limited (NASDAQ: INFY) today announced that it will design and implement the Research Informatics System (RISe) at Elan Pharmaceuticals, Inc (NYSE: ELN), a leading biotechnology company, to accelerate discovery research using a path-breaking co-creation engagement model that leverages Infosys’ existing intellectual property in this field.
“We are confident that partnering and collaborating with Infosys will create a comprehensive informatics platform for our discovery research needs,” said Ajay Shah, Director – Research Informatics, Elan Pharmaceuticals. “We selected Infosys after a competitive Proof-of-Concept phase during which they fully established their credentials and investments in this changing field of discovery research, and demonstrated flexibility and maturity in terms of rapid application development using Agile and Scrum methodologies. With Infosys’ solution and engagement model, Elan will be able to lower costs for scientific operation and facilitate innovation.
As Elan’s informatics system, RISe will leverage Infosys’ Scientific Innovation Solution for knowledge collaboration. Novel ways to unlock disparate data spread across in-house research labs and other commercial or public sources will be presented to scientists in context of their research needs. This will result in, among other things, a customized registry, and inventory and a workflow management system for biological entities.
Elan and its research partners could realize significant gains in research productivity by focused and efficient selection of candidate drugs or biologics with the new RISe. Linking silos of heterogeneous data will not only contribute to a more effective selection process of biologics but could also reduce time to validate them clinically. Furthermore, the new system will reduce time spent on registering and experimenting with bio-entities, increase collaboration, and reduce chances of downstream failure.
Future versions of the software may enable integration of RISe with electronic lab notebook and analytical dashboards which will enable more efficient research knowledge management.
The co-creation engagement model enables Infosys to retain ownership of co-developed IP as part of the implementation. Relevant components of this reference implementation can be reused or repurposed by Infosys to deliver faster business benefits at other Life Sciences organizations.
“Elan’s vision to create a scalable research informatics system for scientists to collaborate better, dovetails perfectly with our investments in solutions that improve scientific innovation and our efforts to streamline discovery research,” said R Arun Kumar, head of Infosys’ Global Life Sciences Practice, Infosys Technologies.
More information can be found at Infosys’ Scientific Innovation Solution website: http://www.infosys.com/offerings/industries/life-sciences/industry-offerings/pages/scientific-innovation-solution.aspx
Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York and Irish Stock Exchanges. For additional information about the company, please visit http://www.elan.com.
About Infosys Technologies Ltd.
Infosys (NASDAQ: INFY) defines, designs and delivers IT-enabled business solutions that help Global 2000 companies win in a Flat World. These solutions focus on providing strategic differentiation and operational superiority to clients. With Infosys, clients are assured of a transparent business partner, world-class processes, speed of execution and the power to stretch their IT budget by leveraging the Global Delivery Model that Infosys pioneered. Infosys has over 109,000 employees in over 50 offices worldwide. Infosys is part of the NASDAQ-100 Index and The Global Dow. For more information, visit www.infosys.com.
Infosys Safe Harbor
Statements in connection with this release may include forward-looking statements within the meaning of US Securities laws intended to qualify for the "safe harbor" under the Private Securities Litigation Reform Act. These forward-looking statements are subject to risks and uncertainties including those described in our SEC filings available at www.sec.gov Opens in new window including our Annual Report on Form 20-F for the year ended March 31, 2009, and our other recent filings, and actual results may differ materially from those projected by forward-looking statements. We may make additional written and oral forward-looking statements but do not undertake, and disclaim any obligation, to update them.
comments powered by